Suttipong Wacharasindhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Suttipong Wacharasindhu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Khomsak Srilanchakon
Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
3 shared publications - Vichit Supornsilchai
Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
3 shared publications - Nattakarn Numsriskulrat
Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine , Chulalongkorn University , Bangkok , Thailand
2 shared publications - Suphab Aroonparkmongkol
Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
2 shared publications - Thanaporn Thaneetrakool
Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
2 shared publications - Krittamate Chatdamrongsakool
Inter-Department of Pharmacology, Graduate School
1 shared publication
Latest Publications
- Open Access
- 15 June 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (6) , 518-523
Intramuscular and subcutaneous gonadotropin-releasing hormone agonist tests for central precocious puberty in girls: a randomized controlled trial
Background: Central precocious puberty (CPP) results from premature activation of the hypothalamic-pituitary-gonadal axis. Although the standard intravenous gonadotropin-releasing hormone (GnRH) stimulation test is often inaccessible, a subcutaneous (SC) GnRH analogue (GnRHa) test is used. However, the conventional SC route presents logistical challenges including prolonged observation times and the need for multiple blood draws. Thus, identifying a more efficient administration route could optimize clinical workflows and enhance patient comfort. This study aimed to determine whether intramuscular (IM) administration is comparable to SC administration by analyzing the time to peak luteinizing hormone (LH) levels.Purpose: To evaluate and compare the time to peak LH levels and diagnostic timing of IM versus SC GnRH stimulation tests in girls with CPP.Methods: This randomized controlled trial enrolled 92 girls with suspected CPP. Participants were assigned via 2:1 block randomization to receive 100 mcg triptorelin acetate via SC (n=62) or IM (n=30) injection. Serial blood samples for LH and follicle-stimulating hormone were collected at 0, 30, 60, 90, and 120 minutes.Results: There were no significant differences between the 2 groups in demographic characteristics. Peak LH responses were most frequent at 30 minutes in both groups (IM, 33.3%; SC, 35.5%; P=0.88). The mean LH levels at 30, 60, 90, and 120 minutes did not differ significantly between groups. Diagnostic confirmation of CPP occurred within 30 minutes in 96.7% and 96.8% of patients in the IM and SC groups, respectively.Conclusion: The IM GnRH stimulation test was comparable to the standard SC test in terms of LH response magnitude and timing.
- 15 June 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (6) , 518-523
Open AccessIntramuscular and subcutaneous gonadotropin-releasing hormone agonist tests for central precocious puberty in girls: a randomized controlled trial
Background: Central precocious puberty (CPP) results from premature activation of the hypothalamic-pituitary-gonadal axis. Although the standard intravenous gonadotropin-releasing hormone (GnRH) stimulation test is often inaccessible, a subcutaneous (SC) GnRH analogue (GnRHa) test is used. However, the conventional SC route presents logistical challenges including prolonged observation times and the need for multiple blood draws. Thus, identifying a more efficient administration route could optimize clinical workflows and enhance patient comfort. This study aimed to determine whether intramuscular (IM) administration is comparable to SC administration by analyzing the time to peak luteinizing hormone (LH) levels.Purpose: To evaluate and compare the time to peak LH levels and diagnostic timing of IM versus SC GnRH stimulation tests in girls with CPP.Methods: This randomized controlled trial enrolled 92 girls with suspected CPP. Participants were assigned via 2:1 block randomization to receive 100 mcg triptorelin acetate via SC (n=62) or IM (n=30) injection. Serial blood samples for LH and follicle-stimulating hormone were collected at 0, 30, 60, 90, and 120 minutes.Results: There were no significant differences between the 2 groups in demographic characteristics. Peak LH responses were most frequent at 30 minutes in both groups (IM, 33.3%; SC, 35.5%; P=0.88). The mean LH levels at 30, 60, 90, and 120 minutes did not differ significantly between groups. Diagnostic confirmation of CPP occurred within 30 minutes in 96.7% and 96.8% of patients in the IM and SC groups, respectively.Conclusion: The IM GnRH stimulation test was comparable to the standard SC test in terms of LH response magnitude and timing.
- Open Access
- 31 August 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (4) , 207-212
Treatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoate
Purpose: Gonadotropin-releasing hormone agonists are the standard treatment for central precocious puberty (CPP). These agonists include leuprolide acetate and triptorelin pamoate, but research data for the relative effectiveness of these 2 treatments in overweight and obese girls experiencing CPP are lacking. In this study, we compared the effectiveness of these 2 therapeutics, leuprolide acetate and triptorelin pamoate, in the treatment of overweight and obese girls affected by CPP.Methods: We enrolled 69 overweight and obese girls with CPP in this retrospective cohort study and classified these participants according to their baseline body mass index (BMI) status, BMI≥1 standard deviation scoer. Leuprolide acetate was administered to 48 of the participants, and the other 21 were treated with triptorelin pamoate. The anthropometric measurements were compared at the beginning and conclusion of the therapy, and luteinizing hormone (LH) suppression levels were assessed 6 months following the completion of treatment.Results: Leuprolide acetate and triptorelin pamoate substantially suppressed LH when administered to overweight and obese girls with CPP. The predicted adult height (PAH) at the conclusion of treatment was comparable between the 2 groups.Conclusion: There was no significant difference in the level of LH suppression and PAH between the 2 groups, overweight and obese girls with CPP treated with leuprolide acetate and those treated with triptorelin pamoate.
- 31 August 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (4) , 207-212
Open AccessTreatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoate
Purpose: Gonadotropin-releasing hormone agonists are the standard treatment for central precocious puberty (CPP). These agonists include leuprolide acetate and triptorelin pamoate, but research data for the relative effectiveness of these 2 treatments in overweight and obese girls experiencing CPP are lacking. In this study, we compared the effectiveness of these 2 therapeutics, leuprolide acetate and triptorelin pamoate, in the treatment of overweight and obese girls affected by CPP.Methods: We enrolled 69 overweight and obese girls with CPP in this retrospective cohort study and classified these participants according to their baseline body mass index (BMI) status, BMI≥1 standard deviation scoer. Leuprolide acetate was administered to 48 of the participants, and the other 21 were treated with triptorelin pamoate. The anthropometric measurements were compared at the beginning and conclusion of the therapy, and luteinizing hormone (LH) suppression levels were assessed 6 months following the completion of treatment.Results: Leuprolide acetate and triptorelin pamoate substantially suppressed LH when administered to overweight and obese girls with CPP. The predicted adult height (PAH) at the conclusion of treatment was comparable between the 2 groups.Conclusion: There was no significant difference in the level of LH suppression and PAH between the 2 groups, overweight and obese girls with CPP treated with leuprolide acetate and those treated with triptorelin pamoate.
- Open Access
- 15 January 2025
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 68 (1) , 91-96
Efficacy of leuprolide acetate versus triptorelin pamoate administered every 3 months for treatment of central precocious puberty
Background: Central precocious puberty (CPP) is typically treated with gonadotropin-releasing hormone (GnRH) agonists. Although numerous GnRH agonist variants are available, limited research has compared the efficacy of leuprolide acetate and triptorelin pamoate administered at 3-month intervals.Purpose: This study aimed to assess the efficacy of CPP treatment with triptorelin pamoate and leuprolide acetate administered at 3-month intervals.Methods: This retrospective cohort study included 116 girls with CPP: 71 treated with leuprolide acetate every 3 months and 45 treated with triptorelin pamoate every 3 months. Anthropometric measurements were compared before and after therapy. At 6 months after the therapy, luteinizing hormone (LH) suppression was evaluated.Results: When administered every 3 months, leuprolide acetate and triptorelin pamoate significantly suppressed LH. The predicted adult height (PAH) and degree of bone age advancement at the end of treatment were comparable.Conclusion: Treatment with leuprolide acetate and triptorelin pamoate every 3 months did not have significantly different effects on LH suppression or PAH.
- 15 January 2025
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 68 (1) , 91-96
Open AccessEfficacy of leuprolide acetate versus triptorelin pamoate administered every 3 months for treatment of central precocious puberty
Background: Central precocious puberty (CPP) is typically treated with gonadotropin-releasing hormone (GnRH) agonists. Although numerous GnRH agonist variants are available, limited research has compared the efficacy of leuprolide acetate and triptorelin pamoate administered at 3-month intervals.Purpose: This study aimed to assess the efficacy of CPP treatment with triptorelin pamoate and leuprolide acetate administered at 3-month intervals.Methods: This retrospective cohort study included 116 girls with CPP: 71 treated with leuprolide acetate every 3 months and 45 treated with triptorelin pamoate every 3 months. Anthropometric measurements were compared before and after therapy. At 6 months after the therapy, luteinizing hormone (LH) suppression was evaluated.Results: When administered every 3 months, leuprolide acetate and triptorelin pamoate significantly suppressed LH. The predicted adult height (PAH) and degree of bone age advancement at the end of treatment were comparable.Conclusion: Treatment with leuprolide acetate and triptorelin pamoate every 3 months did not have significantly different effects on LH suppression or PAH.